An update on hepatitis B, D, and E viruses

Topics in Antiviral Medicine

Volumn 21, Issue 5, 2014, Pages 157-163

  Price, Jennifer ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HBV; HCV; HDV; Hepatitis; HEV; Nucleoside analogue; Nucleotide analogue; Peginterferon alfa

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LAMIVUDINE; LONAFARNIB; PEGINTERFERON ALPHA; RIBAVIRIN; TELBIVUDINE; TENOFOVIR;

ARTICLE; DELTA AGENT HEPATITIS; DISEASE TRANSMISSION; DRUG MEGADOSE; GENE MUTATION; GENE REPLICATION; GENOTYPE; HEPATITIS B; HEPATITIS E; HUMAN; LIVER CIRRHOSIS; MORTALITY; PREVALENCE; RISK FACTOR; TREATMENT RESPONSE; VIRUS REPLICATION;

ADENINE; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B, CHRONIC; HEPATITIS D, CHRONIC; HEPATITIS E; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER FAILURE; ORGANOPHOSPHONATES; TREATMENT OUTCOME;

EID: 84896726274     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (CDC). Viral hepatitis. http://www. cdc.gov/hepatitis. Accessed on September 10, 2013.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486-1500.
3. Servoss JC, Friedman LS. Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis. 2004;8(2):267-281.
4. Hollinger FB, Lau DT. Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am. 2006;35(2):425-461.
5. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000;118(2 Suppl 1):S83-S103.
6. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77-82.
7. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. AASLD practice guidelines. Hepatology. 2013;50(3):1-36.
8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315-1341.
9. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-242.
10. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263-283.
11. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. AASLD practice guideline update. Hepatology. 2009;50(3):661-662.
13. Lok AS. Drug therapy: tenofovir. Hepatology. 2010;52(2):743-747.
14. Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-129.
15. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682-2695.
16. Flink HJ, van ZM, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101(2): 297-303.
17. Marcellin P, Buti M, Gane EJ, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis [Abstract 1375]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 4-8, 2013; San Francisco, California.
18. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27(6):1670-1677.
19. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85.
20. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322-331.
21. Yurdaydin C, Wedemeyer H, Caruntu FA, et al. Pegylated-interferon-a-2a plus tenofovir or placebo for the treatment of hepatitis delta: first results of the HIDIT-2 study [Abstract 24]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Nov. 9-13, 2013; Boston, Massachusetts.
22. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology. 2012;142(6):1388-1397.
23. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected druginduced liver injury. Gastroenterology. 2011;141(5):1665-1672.
24. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367(13):1237-1244.
25. Colson P, Dhiver C, Gerolami R. Hepatitis E virus as a newly identified cause of acute viral hepatitis during human immunodeficiency virus infection. Clin Microbiol Infect. 2008;14(12):1176-1180.
26. Thoden J, Venhoff N, Miehle N, et al. Hepatitis E and jaundice in an HIVpositive pregnant woman. AIDS. 2008;22(7):909-910.
27. Curry JA, Adams N, Crum-Cianflone NF. Acute hepatitis E virus infection in an HIV-infected person in the United States. Ann Intern Med. 2009;150(3):226-227.
28. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361(10):1025-1027.
29. Neukam K, Barreiro P, Macias J, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis. 2013;57(3):465-468.
30. Hajji H, Gerolami R, Solas C, Moreau J, Colson P. Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin. Int J Antimicrob Agents. 2013;41(6):595-597.
31. Dalton HR, Keane FE, Bendall R, Mathew J, Ijaz S. Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med. 2011;155(7):479-480.
32. Jagjit Singh GK, Ijaz S, Rockwood N, et al. Chronic hepatitis E as a cause for cryptogenic cirrhosis in HIV. J Infect. 2013;66(1):103-106.